The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Ethical and legal framework and regulation for off-label use: European perspective
Open accessAbstract
For more than 20 years the off-label use of drugs has been an essential part of the ethical and legal considerations regarding the international regulation of drug licensing. Despite a number of regulatory initiatives in the European Union, there seems to remain a largely unsatisfactory situation following a number of critical descriptions and statements from actors in the field. The present article gives an overview of the ethical and legal framework and developments in European countries and identifies existing problems and possible pathways for solutions in this important regulatory area. In addition to the presentation of the ethical and legal foundations, some attention is given to criticisms from medical practitioners to the current handling of off-label drug use. The review also focuses on the situation confronted by patients and physicians when off-label prescriptions are necessary. Through legal descriptions from a number of countries, possible solutions for future discussion of European health care policy are selected and explained.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The fragmented nature of international regulatory guidelines further complicates their integration into clinical practice.158”
From Off-label and repurposed use of disulfiram beyond alcohol dependence: A systematic review of clinical and preclinical evidence (2026) · cites this paper as [158]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the European Union, for example, off-label use is not regulated centrally; each Member State has developed its own policy.4,158”
From Off-label and repurposed use of disulfiram beyond alcohol dependence: A systematic review of clinical and preclinical evidence (2026) · cites this paper as [158]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Off label and unlicensed drug use among French office based paediatricians
Chalumeau, M. (2000) · Archives of Disease in Childhood · doi:10.1136/adc.83.6.502 · Cited by 169
Defining off-label and unlicensed use of medicines for children: Results of a Delphi survey
Neubert, A. C., Wong, I. C. K., Bonifazi, A., Catapano, M., Felisi, M., Baiardi, P., Giaquinto, C., Knibbe, C. A. J., Sturkenboom, M., Ghaleb, M. A., et al. (2008) · Pharmacological Research · doi:10.1016/j.phrs.2008.09.007 · Cited by 120
Casali, P. G. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm517 · Cited by 80
France's New Framework for Regulating Off-Label Drug Use
Emmerich, J., Dumarcet, N., & Lorence, A. (2012) · New England Journal of Medicine · doi:10.1056/nejmp1208347 · Cited by 73
Calkins, D. R., Fernandopulle, R., & Marino, B. S. (1995) · Medical Entomology and Zoology · Cited by 59
Paediatric clinical pharmacology—at the beginning of a new era
Hoppu, K. (2007) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-007-0390-5 · Cited by 55
Off-label, off-limits? Parental awareness and attitudes towards off-label use in paediatrics
Lenk, C., Koch, P., Zappel, H., & Wiesemann, C. (2009) · European Journal of Pediatrics · doi:10.1007/s00431-009-0956-6 · Cited by 40
Self-citationBücheler, R., Meisner, C., Kalchthaler, B., Mohr, H., Schröder, H., Mörike, K., Schwoerer, P., Schwab, M. G., & Gleiter, C. H. (2002) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/s-2002-35819 · Cited by 38
Reforming Off-Label Promotion to Enhance Orphan Disease Treatment
Liang, B. A., & Mackey, T. K. (2010) · Science · doi:10.1126/science.1181567 · Cited by 25
Off-Label Drug Use in Paediatrics: A World-Wide Problem
Lenk, C. (2012) · Current Drug Targets · doi:10.2174/138945012800675759 · Cited by 21
Self-citationOff-label prescribing in palliative care: A survey of independent prescribers
Culshaw, J., Kendall, D., & Wilcock, A. (2012) · Palliative Medicine · doi:10.1177/0269216312465664 · Cited by 20
A One-Day Survey of Characteristics of Off-Label Hospital Prescription of Psychotropic Drugs
Martin‐Latry, K., Ricard, C., & Verdoux, H. (2007) · Pharmacopsychiatry · doi:10.1055/s-2007-977713 · Cited by 19
Pediatric Uptake of a Newly Available Antipsychotic Medication
Penfold, R. B., Kelleher, K. J., Wang, W., Strange, B., & PAJER, K. A. (2010) · PEDIATRICS · doi:10.1542/peds.2009-1288 · Cited by 15
Mathematisch-naturwissenschaftlichen Fakultät, I., & Bonn, R. F.-W.-U. (2009) · Cited by 8
(2017) · Deutsches Verwaltungsblatt · doi:10.1515/dvbl-2017-0316 · Cited by 7
Lehberger, J., Roth, R., Weingärtner, K., & Heesen, M. A. (2012) · Der Anaesthesist · doi:10.1007/s00101-012-1998-0 · Cited by 5
Huster, S. (2012) · Medizinrecht · doi:10.1007/s00350-012-3142-1 · Cited by 2
Guidi, B., & Nocco, L. (2011) · SSRN Electronic Journal · Cited by 2
Rechtliche Situation von Off-Label Use bis Heilversuch
Sieb, M., & Strasser, S. (2009) · Wiener klinisches Magazin · doi:10.1007/s00740-009-0206-6 · Cited by 1
Research works printed but not linked: 2
- [5]Bücheler R Meisner C Kalchthaler B “Off-label” prescribing of drugs in the ambulatory care of children and adolescents Dtsch Med Wochenschr 2002 127 48 2551 2557 German 12457324
- [31]Deutsch E Spickhoff A Medizinrecht [Medical Law] 6th ed Berlin/Heidelberg Springer 2008 German
Cited by
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19
Cortegiani, A., Ingoglia, G., Ippolito, M., Giarratano, A., & Einav, S. (2020) · Journal of Critical Care · doi:10.1016/j.jcrc.2020.03.005 · Cited by 1,160
Schrier, L., Hadjipanayis, A., Stiris, T., Ross-Russell, R. I., Valiulis, A., Turner, M. A., Zhao, W., Cock, P. A. J. G. D., de Wildt, S. N., Allegaert, K., et al. (2020) · European Journal of Pediatrics · doi:10.1007/s00431-019-03556-9 · Cited by 146
El‐Qutob, D. (2015) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-015-8490-y · Cited by 96
Verbaanderd, C., Rooman, I., Meheus, L., & Huys, I. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01664 · Cited by 82
Off-Label Medication: From a Simple Concept to Complex Practical Aspects
Rusz, C.-M., Ősz, B.-E., Jîtcă, G., Miklos, A., Bătrînu, M.-G., & Imre, S. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph181910447 · Cited by 58
Metadata
- Authors
- Lenk, C., & Duttge, G.
- Affiliations
- Universität Ulm (DE)
- University of Göttingen (DE)
- Corresponding author
- Lenk, Christian
- Venue
- Therapeutics and Clinical Risk Management
- Publisher
- Informa UK Limited
- Published
- 2014-07
- Volume
- 10
- Pages
- 537
- ISSN
- 1176-6336 (ISSN-L)
- 1178-203X
- PMC
- PMC4103928
- OpenAlex
- W2047986597
- Cited by
- 96
- References
- 20
- Citations by year
- 2026: 8 · 2025: 6 · 2024: 3 · 2023: 6 · 2022: 6 · 2021: 12 · 2020: 13 · 2019: 7 · 2018: 12 · 2017: 11 · 2016: 5 · 2015: 7
- FWCI
- 0.90
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Therapeutics and Clinical Risk Management (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- GoeScholar The Publication Server of the Georg-August-Universität Göttingen (Georg-August-Universität Göttingen) (submittedVersion, cc-by-nc)
- GRO (submittedVersion, cc-by-nc)
- Topics
- Health Sciences › Nursing › Issues, ethics and legal aspects › Biomedical Ethics and Regulation
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Health Sciences › Nursing › Issues, ethics and legal aspects › Pharmaceutical industry and healthcare
- Keywords
- off-label drug use, drug regulation, drug approval, pharmaceutical ethics, medical law, European Union health policy, patient rights, comparative health law
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.